Concepedia

Gondi Kumar

GK

Statistics

Publications

52

Citations

5.4K

H-Index

30

Active since

1993

Affiliations

Amgen (United States)(Current)

Abbott Fund

Bristol-Myers Squibb (Switzerland)

Medical University of South Carolina

Abbott (United Kingdom)

Gondi Kumar is an author at Amgen (United States) specializing in pharmacology, medicine, and pharmacokinetics.

Publications per year

1993–2022

52

Publications

52

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · Drug Metabolism and Disposition · 2003 · 784 citations

, , +17

ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

Hing L. Sham, Dale J. Kempf, Akhteruzammen Molla et al. · Antimicrobial Agents and Chemotherapy · 1998 · 470 citations · Full text

, , +16

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir

Dale J. Kempf, Kennan C. Marsh, Gondi Kumar et al. · Antimicrobial Agents and Chemotherapy · 1997 · 420 citations · Full text

, , +17

Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes.

Gondi Kumar, A. David Rodrigues, Alex Buko et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 352 citations

, , +17

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Mary E. Matyskiela, Suzana S. Couto, Xinde Zheng et al. · Nature Chemical Biology · 2018 · 343 citations

, , +5

1–5 of 52